News

Evotec SE announced today that its management will be presenting at and attending investor conferences in September and October.

Evotec SE today reported financial results and corporate updates for the first half of 2019. Group revenues up 16% to € 207.1 m (H1 2018: € 178.9 m). Adjusted Group EBITDA up 51% to € 58.2 m (H1 2018: € 38.6 m). Unpartnered R&D expenses of € 18.7 m (H1 2018: € 10.0 m). Strong liquidity position of € 341.8 m (31 December 2018: € 149.4 m) following issue of € 250 m promissory note (Schuldschein) and final repayment of € 140 m acquisition bridge facility.

Evotec SE will report its financial results for the first half of 2019 on Wednesday, 14 August 2019.

Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents today: Gram-Negative Antibacterials NOW (“GNA NOW”).

Evotec SE today announced that the Company has been notified by its partner Bayer about the successful outcome of a combined Phase I/IIa study with the P2X3 antagonist BAY1817080, originating from the Evotec/Bayer multi-target alliance. 

Evotec SE today announced that the Company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec’s iPSC platform, one of the leading iPSC-based discovery platforms in the industry. 

Evotec SE today announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint Therapeutics’ mission is to develop first and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of therapy-resistant cancers.

Evotec SE today announced that the strategic transaction to acquire Just Biotherapeutics (“Just.Bio”), signed on 20 May 2019, has been completed. The acquisition accelerates Evotec’s long-term strategy to be the industry partner of choice for external end-to-end innovation, strengthening Evotec’s multimodality approach to R&D. Evotec acquired Just.Bio to integrate their cutting-edge machine-learning technologies and agile, flexible methods for the design, development, and manufacturing of biologics into Evotec’s drug discovery offerings.

Just Biotherapeutics, Inc., an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics, announced today that they have entered into an agreement with Teva for the design and development of a high productivity (HP) biomanufacturing process.

Evotec SE announced today that the Company successfully issued a Schuldschein (promissory note) of € 250 m on the capital market. The Schuldschein was placed with a fixed and variable interest rate of on average below 1.5 percent over 3, 5, 7, and 10 years maturity. Following high demand from debt investors, which led to a significant oversubscription of the order book and attractive credit spreads, the initial target volume of € 100 m could be successfully increased to € 250 m.

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc (LSE:SENS) (“Sensyne”), the University of Oxford, Oxford University Innovation Ltd (“OUI”, the university's research commercialisation company), and Oxford Sciences Innovation (“OSI”, the world's largest IP investment company dedicated to a single university) to fund a new BRIDGE called LAB10x. 

Evotec SE today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2019 with very strong supporting majorities.

MaRS Innovation has announced the launch of a fifth project to be developed under the BRIDGE LAB150, a partnership between Evotec SE and MaRS Innovation. The aim of the project is to develop a novel rapid-acting antidepressant with the potential to provide patient relief much faster than conventional treatments.

Evotec SE today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis (“TB”), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant.

Evotec SE announced today that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. 

The 8th edition of DDup is dedicated to our highly innovative iPSC platform, which we started developing more than six years ago with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach highest industrial standards. Today, it represents one of the largest and most sophisticated iPSC platforms in the industry.

Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.

Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences:

Berenberg Conference USA 2019, Tarrytown, NY, USA

2019 RBC Capital Markets Global Healthcare Conference, New York, NY, USA

dbAccess Berlin Conference 2019, Berlin, Germany

Jefferies 2019 Healthcare Conference, New York, NY, USA

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the first quarter of 2019.

Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.

Evotec SE today announced that it has completed the repayment of the € 140 m debt bridge facility Evotec drew down in context of the acquisition of Aptuit in 2017. Effective August 2017, Evotec acquired Aptuit, a partner research organisation for integrated outsourced drug discovery and development, for € 253.2 m in cash. This acquisition was financed through existing cash reserves and a new € 140 m senior debt bridge facility.

Evotec SE and Indivumed GmbH announced today that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”). The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary bioinformatics analysis platform “PanHunter” as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed’s true multi-omics cancer database “IndivuType”. The goal of this precision medicine collaboration is to deliver highly effective and durable treatments with clear strategies for CRC patient stratification.

Evotec SE announced today that it has completed its conversion into a company under European law (Societas Europaea, “SE”) with its registration in the commercial register of the District Court of Hamburg. It will operate under the registered name Evotec SE with the commercial register number HRB 156381 effective immediately and its headquarters will remain in Hamburg. The new legal form has no impact on the Company’s day-to-day operations.

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2018.

Evotec AG and The Mark Foundation for Cancer Research today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics in oncology. The collaboration, for an initial period of two years, is based on Evotec’s new proprietary drug discovery platform TargetAlloMod, which is focused on disrupting cell signalling via a novel mechanism of action. This approach is expected to deliver highly potent and more durable treatments for both clinically validated and novel immuno-oncology targets.

Evotec's partner Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $ 25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program.

Evotec AG will report its financial results for 2018 on Thursday, 28 March 2019. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.

Evotec AG and The Global Antibiotic Research and Development Partnership (“GARDP”) are today announcing the formation of a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance (“AMR”). By joining forces, Evotec and GARDP will leverage their capabilities and networks to address drug-resistant bacterial infections. This includes bringing together GARDP’s clinical expertise and sustainable access commitment with Evotec’s leading drug discovery platform, expertise in medicinal chemistry and pharmacology, as well as its world-leading collection of bacterial pathogens.

Evotec AG announced today that its management will be presenting at and attending the following upcoming conferences: BioCapital Europe, Bankhaus Lampe Deutschlandkonferenz, H.C. Wainwright Global Life Sciences Conference, Kempen & Co Life Sciences Conference.

Evotec AG announced today that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough. As a result of the trial initiation, Evotec received a payment of € 3 m. In October 2012, Evotec and Bayer began their multi-target discovery alliance with the shared goal to discover three clinical candidates with a focus in the field of endometriosis. The successful and productive long-term alliance ended in 2018, generating six first-in-class pre-clinical candidates three of which have progressed into Phase I clinical trials.

MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. The projects aim to develop novel therapeutics for the treatment of cystic fibrosis and of respiratory syncytial virus, respectively. 

Evotec AG and the Helmholtz Centre for Infection Research (“HZI”) announced today a collaboration with the goal to address a major global health threat by developing novel antibiotics that overcome drug-resistant bacterial pathogens. Research activities will initially be focused on the optimisation of cystobactamids, a family of natural antibacterial products with innovative chemical scaffolds that are active against the most dangerous Gram-negative pathogens on the WHO priority list.

Evotec AG and Galapagos NV today announced a global collaboration focused on a novel target for fibrosis and other indications. The collaboration concerns a small molecule programme, currently in pre-clinical development for the treatment of fibrotic diseases of the liver and other organs. The target has been identified and validated using Evotec’s proprietary platforms for fibrotic diseases and NASH. Evotec utilised its in-house assay development and drug screening capabilities to identify small molecule modulators against the target, which remains undisclosed.

Evotec AG mourns the loss of Nobel laureate and Company co-founder Prof. Manfred Eigen, who passed away on 06 February at the age of 91.

Evotec AG announced today that it has earned a $ 2 m milestone payment from Second Genome, Inc., a leading microbiome science-based discovery & development company, for the initiation of a Phase II clinical study of SGM 1019, a first-in-class oral therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). The Phase II trial of SGM-1019 has been initiated following the completion of two successful Phase I trials.

Evotec AG announced today that Cyprotex, an Evotec Company, will participate in the new European collaborative project SCREENED which aims to develop new 3D in-vitro tests to overcome limitations of existing tests. SCREENED aims to develop three-dimensional (3D) cell-based in vitro tests to better characterise the effects of endocrine disruptors on thyroid gland function. This method will overcome the limitations of existing tests, being more sensitive at low doses of exposure to chemicals, and enabling the prediction of their toxicity on human health in a sex-specific manner.

Evotec AG announced today that its strategic alliance with Celgene Corporation (“Celgene”) has reached another important scientific achievement, resulting in Celgene designating a programme and triggering a payment of $ 14.0 m to Evotec. The payment was received by year-end 2018. This scientific achievement was the advancement of a programme into the lead optimisation stage developed from Evotec’s compound library using its induced pluripotent stem cell (“iPSC”)-based screening platform. This programme can be further optimised and progressed towards IND-ready status.

Evotec AG announced today an additional investment of approximately $ 6 m towards Exscientia’s latest funding round (Series B). Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company, has raised $ 26 m in a Series B financing round. Celgene Corporation and GT Healthcare Capital Partners joined as new investors and Evotec, previously the only large external investor, fully participated in this round.

Evotec AG  announced today that its management will be presenting at and attending upcoming conferences:

Evotec AG today announced that its partner Forge Therapeutics has received a second award from CARB-X (Combating Antibiotic Resistant Bacteria) for developing a novel antibacterial therapeutic agent. 

Heading into 2019, it is time to reflect on 2018, which has been very exciting for us in many aspects. We almost doubled the size of our Company and moved towards new goals for worldwide health in many areas.

We wish you peaceful holidays, a very Happy New Year, and much love, success, health and courage for 2019 - all of it squared of course!

Evotec AG announced today that its management will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, USA.

Evotec AG today announced a new integrated drug discovery alliance with LEO Pharma, a global leader in medical dermatology. The collaboration goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years. The collaboration leverages Evotec’s industry-leading hit identification platform including the extensive screening, structural biology and fragment-based drug design capabilities and expertise together with LEO Pharma’s 110-year track record of drug development and advancing science in dermatology.

Evotec AG announced today that the company won the Scrip Award 2018 for “Business Development Team of the Year”. This particular award recognises the achievements of Evotec’s Business Development Team over the last year, which has been characterised by many new alliances and partnerships between Evotec and partners from the pharmaceutical and biotech industry as well as academic institutes.

LAB282, a unique funding-expertise hybrid model to accelerate Oxford therapeutics out of the lab and into the wider world, launched two years ago this month.

Read about what it’s achieved so far, and what’s next for the partnership.

Evotec AG today announced that it has entered into a research collaboration with Immuneering Corporation (“Immuneering”), a worldwide leader in data-driven drug discovery, to discover novel small molecules for rare hereditary metabolic diseases. The research collaboration brings together Evotec’s leading induced pluripotent stem cell (“iPSC”) platform and broad drug discovery capabilities with Immuneering’s unique Artificial Intelligence-driven drug discovery platform to accelerate ligand identification for novel targets.

Evotec AG today reported financial results and corporate updates for the first nine months of 2018: Strong operational and scientific performance; 57% increase in group revenues, 77% increase in adjusted group EBITDA; Strong outlook for 2018 confirmed and good underlying business indications for 2019; Webcast and conference call today at 02.00 pm CET

Evotec AG announced today that the company has won one of the prestigious “Technology Fast 50” awards with which Deloitte honours the fastest-growing innovation drivers within the technology sector. At yesterday’s award ceremony, Evotec received the prize for “Sustained Excellence” which recognises the Company’s long-term growth, innovation capability, entrepreneurial spirit, as well as its sustainable corporate management.

Evotec AG announced today that its management will be presenting and attending the following upcoming conferences:

Jefferies London Healthcare Conference 2018, London, UK

15th Kempen London Conference, London, UK

German Equity Forum 2018, Frankfurt am Main, Germany

16th Berenberg European Conference, Surrey, UK

Evotec AG will report its financial results for the first nine months of 2018 on Tuesday, 13 November 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec partner Facio Therapies (“Facio”) announced today that oral treatment with one of Facio’s lead candidates results in significant reduction of the human muscle-toxic DUX4 protein in mice engrafted with human FSHD-affected muscle cells. Facio is the first in the FSHD field to achieve proof of principle in an animal model (“in vivo”).

NCL foundation announces today that together with the biotechnology Company Evotec AG it supports a three-year PhD programme for research into juvenile neuronal ceroid lipofuscinosis (NCL). Under scientific supervision by Dr Guido Hermey (Hamburg University), the PhD programme will be based in the facilities and laboratories of Evotec AG. 

Evotec AG and Ferring Pharmaceuticals today announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions.

Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients’ symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression.

Evotec AG announced today that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas.

MaRS Innovation announced today the second project to be developed under their LAB150 partnership with Evotec. The project aims to develop a novel therapeutic approach to treat glaucoma, an irreversible neurodegenerative disease of the optic nerve which can lead to blindness. This project is derived from a decade of research investigating the molecular pathways underlying tissue damage and repair in the eye in the laboratory of Dr. Jeremy Sivak, Senior Scientist at UHN’s Krembil Research Institute, in Toronto.

In this 7th DDup issue, we delve into the unique new kidney platforms poised to change the trajectory of kidney disease research and therapeutics development.

Evotec AG and  Almirall, S.A. today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signalling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis.

Evotec AG announced today that Evotec and Celgene Corporation (“Celgene”) have entered into a third long-term strategic drug discovery and development partnership in the field of targeted protein degradation. In this collaboration, Evotec and Celgene will leverage Evotec’s Panomics platform in order to identify drug targets which are traditionally difficult to track. Evotec’s Panomics platform applies in particular high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates on the basis of comprehensive cell biological profiles.

Evotec AG announced today that its shares will be included in the MDAX as of 24 September 2018 as announced by Deutsche Börse on 05 September 2018. This dual listing of the Evotec shares in both TecDAX and MDAX results from the rule changes regarding the inclusion of companies in the MDAX, SDAX and TecDAX.

Evotec AG announced today that its management will be presenting and attending at the following conferences:

Goldman Sachs 8th Annual Biotech Symposium, London, UK

J.P. Morgan Cazenove Pan-European Small/Mid Cap Conference, London, UK

Morgan Stanley 16th Annual Global Healthcare Conference, New York, USA

Baader Investment Conference, Munich, Germany

Berenberg and Goldman Sachs Seventh German Corporate Conference, Munich, Germany

Cantor Global Healthcare Conference 2018, New York, USA

Evotec AG today announced that CHDI Foundation, Inc. (“CHDI”) has extended its collaboration with Evotec through to 2023. Over this period, CHDI may fund up to 75 full-time scientists at Evotec. The collaboration was initiated in 2006 and has grown considerably over this period to fully utilise Evotec’s best-in-class integrated neuroscience platform. The extension of this collaboration is a further validation of Evotec’s investment in new technologies and capabilities in support of driving innovative drug discovery collaborations. 

Evotec AG today announced that CENTOGENE AG, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, and Evotec entered into a global strategic collaboration agreement for joint drug discovery projects, developing compounds to treat rare genetic diseases.

Evotec AG today announced a strategic alliance with Novo Nordisk to discover and develop novel small molecule therapies to treat patients suffering from diabetes and obesity as well as co morbidities such as nonalcoholic steatohepatitis (“NASH”), cardiovascular diseases, and diabetic kidney disease.

Evotec AG announced today that Haplogen GmbH (“Haplogen”), a Vienna-based biotechnology company and collaboration partner of Evotec, has entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (“COPD”).

Evotec AG today reported financial results and corporate updates for the first half of 2018. 

Evotec AG will report its financial results for the first half of 2018 on Thursday, 09 August 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Evotec AG announced today that it completes the repayment of 50% of the € 140 m debt bridge facility within the first year of being granted in context of the Aptuit acquisition in 2017. Effective August 2017, Evotec acquired Aptuit, a partner research organisation for integrated outsourced drug discovery and development, for € 253.2 m in cash. This acquisition was financed through existing cash reserves and a new € 140 m senior debt bridge facility.

Evotec AG announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of € 4 m to Evotec.

Evotec AG today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research portfolio, has been successfully closed with effect from 01 July 2018. 

Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached its second beta cell therapy milestone, resulting in a payment of € 3 million to Evotec. This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models.

Evotec AG today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2018 with the required majorities.

Evotec AG today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. This successfully seals the exclusive negotiations between the two companies and completion of the required legal social process, initiated on 08 March 2018.

Evotec AG announced today the formation of the LAB591 academic BRIDGE with Arix Bioscience plc (“Arix”, London Stock Exchange: ARIX ) and the Fred Hutchinson Cancer Research Center (“Fred Hutch”). LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development.

Evotec AG announced today that the Company will receive a $ 6 m payment from Celgene following Celgene’s decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

Evotec AG today announced that it has expanded its iPSC platform through a licence agreement with ID Pharma. The non-exclusive licence enables Evotec to both work with and differentiate induced pluripotent stem cells (“iPSC”) produced with ID Pharma’s Sendai virus (“SeV”) vector technology.

Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.

Evotec AG today reported financial results and provided corporate updates for the first quarter of 2018.

Evotec AG today announced a strategic collaboration with Carna Biosciences, Incorporated (“Carna”). Carna will access Evotec’s INDiGO platform to accelerate the development of its programme CB-1763, which is being developed for the treatment of blood cancer, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration.

Evotec AG announced today that its management will be presenting at the Deutsche Bank 43rd Annual Health Care Conference in Boston, USA, at the Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, USA, at the Berenberg USA Conference 2018 in Tarrytown, USA, at the Jefferies 2018 Global Healthcare Conference in New York, USA, and at the dbAccess Berlin Conference in Berlin, Germany.

Evotec AG today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its existing service offering in the CRISPR gene editing space. The new licence from ERS Genomics Limited complements and expands Evotec’s existing CRISPR licences through the Broad Institute with gene editing technology from Emmanuelle Charpentier and others.

Evotec AG will report its financial results for the first quarter of 2018 on Wednesday, 09 May 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2018. The conference call will be held in English.

Five years after initiating our endometriosis alliance with Bayer, we draw some very important lessons from one of our key performance-based alliances – and share our insights.

Evotec AG announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176 million women worldwide.

Evotec AG announced today a strategic collaboration with Petra Pharma Corporation (“Petra”). Through the collaboration, Petra will access Evotec’s INDiGO platform to accelerate the development of its lead programme Petra-01, which is being developed for a range of oncological indications, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration by the close of 2018.

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2017.

Evotec AG has launched its accelerated drug development service INDiGO®. With the launch of INDiGO®, Evotec’s expertise and capabilities are uniquely combined under one roof to deliver better drug candidates to patients faster and more efficiently than standard industry approaches. 

Evotec AG will report its financial results for 2017 on Wednesday, 28 March 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2018. The conference call will be held in English.

Evotec AG today announced that it has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden ("CRTD") to discover novel small molecule candidates for retinal diseases. 

Evotec AG announced today that LAB282, the £ 13 m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is celebrating its first year of operation after successfully accelerating 12 drug discovery and development projects at the University.

Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec

Evotec AG announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of EUR 2.00 m to Evotec.

Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, today announced that the first patient has been dosed in the phase 1 clinical programme of CT7001

Evotec AG announced today that its management will be presenting at upcoming investor conferences

Evotec AG today reported financial results and corporate updates for the first nine months of 2017.

Evotec AG today announced a strategic collaboration on microfluidics technology including induced pluripotent stem cell ("iPSC") differentiation with leading academic institutions in the UK and Italy to accelerate the discovery of novel drugs to treat kidney diseases.

Evotec AG will report its financial results for the first nine months of 2017 on Wednesday, 08 November 2017. 

Evotec AG and TESARO, Inc. today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology (IO) target. 

Evotec AG announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec.

Evotec AG and Exscientia Ltd ("Exscientia") today announced that Evotec has made a EUR 15 m investment to take a minority stake in Exscientia.

Evotec AG and MaRS Innovation ("MI") today announced the launch of "LAB150".

Evotec AG and the European Investment Bank ("EIB") announced today that the EIB has granted Evotec an unsecured loan facility of up to EUR 75 m to support Evotec's Innovate strategy.

Evotec AG and ABIVAX today announced a strategic collaboration to discover and develop novel treatments for multiple serious viral infectious diseases.

Evotec AG announced today that its management will be presenting at upcoming investor conferences.

Evotec AG today announced that, effective mid-August 2017, it has successfully completed the acquisition of Aptuit as announced in detail on 30 July 2017.

Evotec AG today reported financial results and corporate updates for the first half of 2017.

Evotec AG today announced a strategic collaboration on induced pluripotent stem cell ("iPSC") technology with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort.

Evotec AG will report its financial results for the first half of 2017 on Thursday, 10 August 2017.

Evotec AG and Aptuit announced today that they have entered into a definitive agreement under which Evotec will acquire Aptuit for $ 300 m.

Evotec AG announced today an integrated drug discovery collaboration with STORM Therapeutics ("STORM") to develop new small molecule epigenetic drugs for oncology and other therapeutic areas.

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.

Evotec AG announced today that the Company has been awarded a 'Programm für Innovation' ("PROFI") grant for a period of two years from the  Hamburgische Investitions- und Förderbank

Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. ("Censo") to source and provide patient-derived induced pluripotent stem cells ("iPSC") to support Evotec's broad iPSC platform.

Evotec AG announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University.

Evotec AG announced today that it will make a strategic investment as part of Facio Therapies' ("Facio") 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy ("FSHD") community (Total volume: EUR 4.8 m).

Evotec AG was awarded the European Mediscience Award for “Company of the Year”. 

Evotec AG today announced that it has joined the NURTuRE consortium to drive kidney disease
focused drug discovery based on patient derived-data.

Evotec AG today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting, which took place today, with the required majority.

Forge Therapeutics and Evotec present first efficacy data for Lpxc inhibitor in uti model at  ASM MICROBE 2017

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another significant pre-clinical milestone, triggering a payment of approx. EUR 5 m to Evotec for the transition of a programme into pre-clinical development for the treatment of endometriosis.

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at upcoming investor conferences

Evotec AG today reported financial results and corporate updates for the first quarter of 2017.

Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached an important milestone, triggering a payment of EUR 3.0 m to Evotec, for achieving pre-clinical proof-of-concept.

Evotec AG today announced that its partner Forge Therapeutics ("Forge") has received a research award from CARB-X (Combating Antibiotic Resistant Bacteria) of $ 8.8 m to advance its novel Gram-negative antibiotic programme targeting LpxC for the treatment of bacterial infections.

Evotec AG today announced its financial results and corporate updates for the fiscal year ended 31 December 2016.

Evotec AG and Business France today released their short film about Evotec’s research site in Toulouse, France, under the headline: “Evotec found Business in France – Great story, short film”.

Evotec AG is pleased to announce that LAB282, the £ 13 m (over EUR 15 m) drug discovery partnership with Oxford University, has made its first wave of awards, backing projects targeting cardiovascular diseases and infectious diseases.

Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash. Evotec will issue 13,146,019 new shares to Novo A/S (Denmark). Novo A/S is the independent holding company for the Novo Group.

Evotec AG today announced that Cyprotex, a company wholly owned by Evotec AG, has completed the relocation of its UK operations from Macclesfield to Alderley Park.

Evotec AG today announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan.

Evotec AG and MaRS Innovation today announced the launch of Fibrocor Therapeutics LP ("Fibrocor"), a Toronto-based company focused on developing first-in-class therapeutics targeting fibrotic diseases. 

Evotec AG today announced a promising research result in the field of picornaviruses published in a scientific article by Dr Thijn Brummelkamp, the co-founder of Haplogen GmbH, a biotech company based in Vienna, Austria, that develops antiviral therapeutics in a co-owned partnership with Evotec.

Evotec AG announced today that it will extend its existing relationship with Eternygen GmbH ("Eternygen") by becoming an investor in addition to being a pre-clinical drug discovery partner. 

Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases.

Evotec AG today announced the successful closing of the acquisition of 100% shares in Cyprotex PLC, a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in the UK.

Evotec AG today announced a strategic alliance with Forge Therapeutics, Inc. ("Forge") to advance its novel Gram-negative antibiotic programme targeting "LpxC" for the treatment of bacterial infections including those caused by drug resistant 'superbugs'.

Evotec AG today announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck's portfolio of genome editing technologies with Evotec's versatile screening platforms and disease expertise.

Evotec AG today announced a novel strategic partnership with the University of Oxford, Oxford University Innovation Ltd, OUI (the university's research commercialisation company) and Oxford Sciences Innovation, OSI (the world's largest IP investment company dedicated to a single university) aimed at accelerating the translation of basic biomedical research from Oxford into new therapeutics.

Evotec AG today reported financial results and corporate updates for the first nine months of 2016.

Evotec AG today announced that it has made an offer to acquire Cyprotex PLC ("Cyprotex", AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK.

Evotec AG today announced a collaboration with UCB to provide a broad range of in vitro pharmacology services.

Evotec AG announced today that in line with its strategy to participate in promising corporate formations it will deepen its already existing relationship with Carrick.

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has reached another key pre-clinical milestone for the transition of a project from the alliance portfolio into pre-clinical development.

Evotec AG today announced a multi-target collaboration with C4X Discovery Holdings plc ("C4XD").

Evotec AG announced today that the Company has entered into a research collaboration with Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research ("Inserm").

Evotec AG today announced that Evotec and Bayer have entered into a five-year, multi-target research partnership in kidney disease. 

Evotec AG today reported financial results and corporate updates for the first half of 2016.

Evotec AG announced today that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.

Evotec AG announced today a collaboration with Antibiotic Research UK ("ANTRUK") to identify alternative means of treating infections that are resistant to currently available antibiotics.

Evotec AG announced today that the Company has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology.

Evotec AG announced today that the investment company Ellersbrook GmbH & Co. KG, ("Ellersbrook"), Germany, will invest into Evotec's internal TargetNASH programme. 

Evotec AG today announced that Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for a further three years to discover novel small molecule therapeutics.

Evotec AG today reported financial results and corporate updates for the first quarter of 2016.

Evotec AG and Exscientia Ltd (Dundee, UK) today announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies.

Evotec AG today announced a multi-year compound management agreement with Pierre Fabre Laboratories, the 2nd largest private French pharmaceutical group.

Evotec AG today announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders.

Evotec AG today announced its financial results for the fiscal year ended 31 December 2015.

Evotec AG today announced the achievement of a key pre-clinical milestone in the ongoing alliance with its research partner Padlock Therapeutics, Inc. ("Padlock").

Evotec AG today announced that it has been awarded a research grant from The Michael J. Fox Foundation ("MJFF") to further develop Evotec's TargetaSN (Targetalpha-synuclein) programme for the treatment of Parkinson's disease.

Evotec AG today announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. ("Janssen") for the transition of a project into further drug discovery process.

Evotec AG today announced an EVT Execute collaboration aimed at providing a complete solution to UCB's global sample management requirements.

Evotec AG today announced an extension of an existing collaboration with Spero Therapeutics, based in Cambridge, Massachusetts, aimed at discovering and developing new and ground-breaking therapeutics for Gram-negative bacteria to treat serious infections and address the growing threat to global public health resulting from antibiotic resistance.

Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached two important pre-clinical milestones for the transition of two projects from the alliance portfolio into late-stage discovery and pre-clinical development for the treatment of endometriosis.

Evotec AG today announced an EVT Execute collaboration with Beyond Batten Disease Foundation aimed at discovering and developing new treatments for juvenile Batten disease, a rare, fatal autosomal recessive neurodegenerative disorder. 

Evotec AG today announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute, Department of Health and Human Services. 

Evotec AG today announced that it increases its financial guidance for the current year. 

Evotec AG today announced that it has signed an agreement on a four-year research collaboration with Pfizer Inc.

Evotec AG today announced that CHDI Foundation, Inc. has extended and expanded its collaboration with Evotec through to August 2018.

Evotec AG today reported financial results and corporate updates for the first half of 2015.

Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, today announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.

Evotec AG and Sanofi today announced a strategic collaboration in the field of diabetes.

Evotec AG today announced that it has become part of a research initiative between a newly established for-profit company of the Gladstone Institutes called Cure Network Ventures, Inc. and Dolby Family Ventures.

Evotec AG  was updated today by its partner Roche on the initial results of the Phase IIb trial with Sembragiline, a MAO-B inhibitor for the treatment of Alzheimer's disease.

Evotec AG and Facio Therapies announced today that they have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD, a muscle wasting disease.

Evotec AG today announced it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan.

Evotec AG today announced its financial results for the fiscal year ended 31 December 2014.

Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi.

Evotec AG and Second Genome, Inc. today announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases.

Evotec AG today announced a research collaboration with C4X Discovery Holdings plc to optimise Orexin-1 selective inhibitors discovered through C4XD's unique NMR technology.

Evotec AG today announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process.

Evotec AG and Padlock Therapeutics, Inc. announced today that they have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases and have further extended the collaboration that was first signed in January 2014.

Evotec AG today announced a research collaboration with the laboratories of Prof. Roger Briesewitz at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

Evotec AG disclosed today that it achieved multiple milestones in ongoing alliances with its strategic research partners.

Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years.

Evotec AG today reported financial results and corporate updates for the first nine months of 2014.

Evotec AG announced today that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis.

Evotec AG announced today that it has entered into three novel research projects for the treatment of Multiple Sclerosis supported by research funds from the German Federal Ministry of Education and Research.

Evotec AG announced today after careful evaluation that it will take legal steps against Israel-based Andromeda Biotech, Ltd. to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277®.

Evotec AG and the Jain Foundation Inc. today announced that they have further extended and expanded the collaboration first signed in 2012 and extended last year.

Evotec AG today announced that CHDI Foundation, Inc. has extended and restated its collaboration with Evotec through 2017.

Evotec AG was informed that US company Hyperion Therapeutics, Inc. is terminating the development of DiaPep277® for newly diagnosed Type 1 diabetes.

On Friday, the motor neuron research group took on the ALS Ice Bucket Challenge to help raise awareness for this rapidly progressive neurodegenerative disease.

Evotec AG today announced the start of a multi-year compound management agreement between Evotec (US) Inc. and Medicines for Malaria Venture in support of MMV's Malaria and Pathogen Box initiatives.

Evotec AG today reported financial results and corporate updates for the first half of 2014.

Evotec AG today announced the successful achievement of the first milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of three selected targets from the TargetAD database.

Evotec AG today announced the publication of its fifth DDup edition.

Evotec AG announced today an exclusive strategic collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organisations for internal and external drug discovery projects.

Evotec AG was awarded the European Mediscience Award for best communication at a celebratory dinner on Thursday, 19 June 2014, in London. 

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 1.0 m to Evotec.

Evotec AG today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting.

Evotec AG today announced the acquisition of all shares in Euprotec Ltd, a UK-based specialist contract research organisation.

Evotec AG today reported financial results and corporate updates for the first quarter of 2014.

Evotec AG and Eternygen GmbH, a privately owned biopharmaceutical company, today announced a drug discovery collaboration to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform and broad expertise in drug discovery and pre-clinical development.

Evotec AG today announced the successful achievement of a milestone in its biomarker alliance with Roche.

Evotec AG announced today a research collaboration and licensing deal with Debiopharm GroupTM Lausanne, Switzerland.

Evotec AG today announced that it has entered into a research alliance with Panion Ltd, a subsidiary of Convergence Pharmaceuticals Holdings Ltd. Convergence is a UK company focused on the development of novel, high value analgesics to treat chronic pain.

Evotec AG today announced its financial results for the fiscal year ended 31 December 2013, which are in line with the revised expectations communicated in the fourth quarter 2013.

Evotec AG today announced the acquisition of the Germany-based Bionamics GmbH.

Evotec AG today announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine.

Evotec AG today announced that it is adjusting its guidance regarding Group revenues.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in November triggering revenues of € 4.0 m to Evotec.

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the third quarter and first nine months of 2013 ending 30 September 2013.

Evotec AG today announced a collaboration with the Johnson & Johnson Innovation Center in California to identify new targets for Alzheimer's disease drug discovery and development.

Evotec AG announced today that it has entered into an integrated research collaboration with The Leukemia & Lymphoma Society. 

Evotec AG today announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology.

Evotec AG today announced that it has signed an agreement with AstraZeneca in the field of kidney diseases.

Evotec AG today announced the publication of its fourth DDup edition.

Evotec AG announced today that its R&D Day 2013 will take place on 22 October 2013 in New York City, USA. 

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of EUR 4.0 m to Evotec.

Evotec AG today announced a second research collaboration, TargetEEM, with the laboratory of Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator.

Evotec AG  today announced that its research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of € 2.0 m to Evotec.

Evotec AG announces today the publication of a DDup Special Edition, which focuses on its drug discovery service offering.

Evotec AG today announced a strategic partnership with the Harvard Stem Cell Institute to identify compounds that prevent or slow down the loss of motor neurons, which is characteristic of the human disease amyotrophic lateral sclerosis.

Evotec AG today announced a 9.9% increase of its share capital. 

Evotec AG and the Jain Foundation today announced that they have extended and expanded their research collaboration leveraging Evotec's assay development and screening capabilities to support the Jain Foundation's goals of understanding and curing dysferlinopathy.

Evotec AG today reported financial results and corporate updates for the first half of 2013.

Evotec AG today announced that Evotec and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, have entered into a research collaboration with the objective of leveraging Evotec's advanced chemical proteomics services to support compounds in development at Dow AgroSciences.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone in June triggering revenues of EUR 1.5 m to Evotec.

Evotec AG today announced that it will close its Chemistry Operations in Thane, India.

Shareholders of Evotec AG today approved the actions of the members of the Management Board and the Supervisory Board for the fiscal year 2012 at the Annual General Meeting.

Evotec AG today announced a research collaboration with Harvard University aimed at discovering and developing novel anti-bacterial agents based on a highly validated target family involved in bacterial cell wall biosynthesis.

The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG today announced a research collaboration aimed at discovering and commercialising novel cancer treatments based on epigenetic drug mechanisms.

Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States.

Evotec AG today announced an auspicious step in research from Harvard University.

Evotec AG today announced that it has extended its drug discovery alliance with Genentech, a member of the Roche Group, for three additional years.

Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2012.

Evotec AG today announced that Dr Werner Lanthaler, Chief Executive Officer of Evotec, will resume his role as Chief Executive Officer of the Company with immediate effect after a period of leave due to health reasons.

Evotec AG today announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone.

Evotec AG today announced that it has entered into a strategic partnership with Yale University.

Evotec AG today announced that it has expanded the scope of its collaboration with MedImmune, the global biologics arm of AstraZeneca, after hitting a key milestone.

Evotec AG today announced the acquisition of all shares in Cell Culture Service GmbH, a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and Pharmaceutical companies.

Evotec AG today announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer.

Evotec AG today announced that it has entered into a license agreement with Janssen Pharmaceuticals, Inc. regarding its NR2B subtype selective NMDA-antagonist portfolio for development against diseases in the field of depression.

Evotec AG announced today that it has entered into a collaboration with Probiodrug AG, a privately owned biopharmaceutical company focused on the development of innovative drugs for the treatment of major age related diseases.

Evotec AG today announced that it has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research.

Evotec AG and Haplogen GmbH have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases.

Evotec AG today reported financial results and corporate updates for the third quarter and first nine months of 2012 ending 30 September 2012.

Evotec AG today announced that CHDI Foundation, Inc., a privately-funded not-for-profit research organisation dedicated to developing therapies for Huntington's disease, has extended its collaboration with Evotec until the end of 2015.

Evotec AG announced today that Dr Werner Lanthaler, Chief Executive Officer of Evotec, was awarded the prize 'Turnarounder of the Year 2012'.

Evotec AG  today announced that it has received a pre-clinical milestone from its Drug Discovery Collaboration with Novartis.

Evotec AG today announced that Dr Werner Lanthaler, CEO of Evotec, will temporarily stand down from his role within the company due to health reasons.

Evotec AG today announced that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.

Evotec AG and Aspireo Pharmaceuticals Limited an Israeli biopharmaceutical company focused on the development of a novel somatostatin analogue, announced today that they have entered into a strategic advisory agreement for support in the development and partnering of Aspireo's Somatoprim.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec.

Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the National Institutes of Health, Department of Health and Human Services, for the operation of a Small Molecule Repository.

Evotec AG today reported financial results and corporate updates for the second quarter and first half of 2012 ending 30 June 2012.

Evotec AG today announced that it has licensed to Janssen Pharmaceuticals, Inc. a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. 

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 4.0 million to Evotec.

Evotec AG is proud to announce the addition of Agilent Technologies' RapidFire Mass Spectrometry analysis capabilities to their High Throughput Screening facilities in Hamburg.

Evotec AG today reported financial results and corporate updates for the first quarter of 2012.

Evotec AG and 4-Antibody AG today announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service.

Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the United States EPA. 

Evotec AG and Conba Pharmaceutical Co., Ltd. announced today the grant of a development and marketing license on EVT 401, a selective, small molecule P2X7 antagonist, for human indications with exception of ophthalmological, chronic obstructive pulmonary disease and endometriosis in China.

Evotec AG today announced that it has extended and expanded its medicinal chemistry collaboration with Active Biotech AB, to further advance an existing programme, which has entered the lead optimisation phase.

Evotec AG today announced the publication of its second edition of DDup, which focuses on neurodegeneration diseases, major disorders with inadequate standards of care. 

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2011.

Evotec AG and IR Pharma today announced that they have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases.

Evotec AG today announced the completion of the squeeze-out process to acquire all of the remaining shares of DeveloGen AG from its minority shareholders.

Evotec AG today announced a second strategic alliance with Harvard University, this time including Brigham and Women's Hospital aimed at discovering and developing new biomarkers and treatments in the field of kidney disease.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 2.5 million to Evotec.

Evotec AG today reported financial results and corporate updates for the first nine months of 2011.

Evotec AG today announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments.

 Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.

Evotec AG today announced that it has entered into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology.

Evotec AG today announced that it has signed a Share Purchase Agreement to acquire the remaining 30% of equity of its Joint Venture with DIL Limited, India for €1.7M.

Evotec AG and Roche AG announced today that they have entered into an exclusive worldwide agreement for the development and commercialization of Evotec's MAO-B inhibitor in patients with Alzheimer's disease.

Evotec AG  today announced that its research alliance with Boehringer Ingelheim has achieved a milestone triggering a payment of EUR 4 million to Evotec.

Evotec AG today announced that it has entered into a world-wide license and collaboration agreement with a top tier animal health company that intends to develop the proprietary Evotec compound EVT401, a selective, small molecule P2X7 antagonist, in the companion animal market.

Evotec AG today reported financial results and corporate updates for the first half of 2011.

Evotec AG today announced that it has entered into a three year integrated drug discovery collaboration with UCB to identify small molecule modulators of priority biological targets, selected by UCB, involved in CNS disorders.

Evotec AG today announced the achievement of specific success criteria in an ion channel research collaboration with Ono Pharmaceutical Co., Ltd. and the receipt of a milestone payment. 

Evotec AG and Roche today announced a collaboration in novel protein-activity based biomarkers for Roche's oncology drugs under development.

Evotec AG today announced that it has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

Evotec AG and Galapagos NV today announced that Evotec has acquired Compound Focus, Inc., the compound management business of BioFocus, a Galapagos Company. 

Evotec AG today announced that a back-up compound in its strategic alliance with Boehringer Ingelheim has advanced into a Phase I clinical trial. Evotec will receive a milestone payment of EUR 2.0 million.

Evotec AG today announced that it has entered into a strategic alliance with PsychoGenics Inc. to provide integrated CNS drug discovery solutions to pharmaceutical and biotech companies.

Evotec AG and Roche today decided to voluntarily terminate the first proof-of-concept study in treatment-resistant depression with their NR2B sub-type selective NMDA antagonist EVT 101.

Evotec AG today reported financial results and corporate updates for the first quarter of 2011.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has achieved a twelfth milestone triggering a payment of EUR 2.0 million to Evotec.

Evotec AG today announced that it has completed the acquisition of Kinaxo Biotechnologies GmbH, a privately held drug discovery alliance company supporting the development of targeted drugs.

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2010.

Evotec AG today announced the establishment of a research collaboration with Harvard University and the Howard Hughes Medical Institute aimed at discovering and developing new  treatments in the field of diabetes.

Evotec AG today announced that it has entered into a collaboration with ChemBridge, to further enhance its screening library.

 Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.

Evotec AG today announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec.

Evotec AG announced today that on 30 December 2010 it filed a Form 15F with the Securities and Exchange Commission to deregister and terminate its reporting obligations under the U.S. Securities Exchange Act of 1934 for its American Depositary Shares and its ordinary shares underlying the ADSs.

Evotec AG today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune, in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells.

Evotec AG today announced that it has signed within the "NEU²-Consortium" framework and partially funded by the Federal Ministry of Education and Research, an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease.

Evotec AG today reported financial results and a corporate update for the first nine months of 2010.

Evotec AG today announced that it has entered into a license and collaboration agreement with Zhejiang Jingxin Pharmaceutical Co., Ltd for EVT 201, a novel potential treatment for insomnia.

Evotec AG today announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM, a novel target involved in perception of various pain mechanisms.

Evotec AG today announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets.

Evotec AG today announced that it has entered into a collaboration with Almirall S.A., to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases.

Evotec AG today announced the Closing of the agreement to acquire DeveloGen as announced in detail on 14 July 2010.

Evotec AG today reported financial results and corporate updates for the first half of 2010.

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec.

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to € 14m in shares plus performance-related deferred payments.

Evotec AG today announced the start of the proof-of-concept Phase II study in treatment-resistant depression with its NR2B subtype selective NMDA receptor antagonist EVT 101.

Evotec AG today announced that it has achieved a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of EUR 2.5 million.

Evotec AG today announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials.

Evotec AG today reported financial results and corporate updates for the first quarter of 2010.

Evotec AG today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group, to discover novel small molecule therapeutics. 

Evotec AG today announced that it will receive funding of up to EUR 1.5 million from the German Federal Ministry of Education and Research to advance its H3 receptor antagonist programme into the clinic.

Evotec AG today reported financial results and corporate updates for the year ended 31 December 2009.

Evotec AG has been named the M&A Advisor Healthcare Turnaround Company of the Year for the development and implementation of the 'Evotec 2012 - Action Plan to Focus and Grow'.

Evotec AG today announced that it has signed an agreement with Hypha Discovery Ltd. Under the terms of the agreement, Evotec will be able to provide its screening clients with access to Hypha’s MycoDiverse™ natural product collection for use as part of its hit and lead identification services.

Evotec AG today announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

Evotec AG today announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche.

Evotec AG today announced that it has extended its research agreement with Cubist Pharmaceuticals, Inc. to the end of 2010.

Evotec AG today announced that it has signed an agreement with Vifor Pharma. 

Evotec AG today announced the extension of its collaboration with CHDI Foundation, Inc. through to the end of 2012.

Evotec AG today announced that it has received a milestone payment from Ono Pharmaceutical Co., Ltd. from its research collaboration aimed at identifying novel inhibitors for a protease target.

Evotec, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has been granted up to € 2.5 m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase for potential use in neuroprotection.

Evotec AG today reported results and corporate updates for the third quarter and nine months ended September 30, 2009.

Evotec AG a leading provider in the discovery and development of novel small molecule drugs today announced that it plans to voluntarily delist its American Depositary Shares from the NASDAQ stock market and concentrate its share trading on the recently re-entered TecDAX platform.
 

Evotec AG today announced that it has extended the research collaboration with Boehringer Ingelheim for a further 4 years.

Evotec AG today announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs and DiscoveRx Corporation, a premier provider of innovative cell based assay solutions, today announced a co-marketing agreement for the screening of GPCR's and other targets.

Evotec AG today announced that it has extended its current research collaboration with Ono Pharmaceutical Co., Ltd. and initiated a new discovery collaboration.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that the company has achieved an important milestone with Cardioxyl Pharmaceuticals under a collaboration agreement for the compound, CXL-1020, that has successfully moved into clinical testing.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has entered into a research agreement with Biogen Idec, a leading biopharmaceutical company headquartered in Cambridge, Mass., USA.

Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today the Phase I clinical study initiation for EVT 103, a small molecule NR2B-selective NMDA receptor antagonist.

Evotec AG announced today that the acquisition of the controlling majority stake of Research Support International Private Limited has been successfully completed and that RSIPL is a 70%, majority owned subsidiary of Evotec as of August 31, 2009.

Evotec AG today reported results and corporate updates for the second quarter 2009.

Evotec AG and DIL Limited, India, announced today the signing of a definitive agreement to acquire a 70% controlling majority stake of the drug discovery service company RSIPL for EUR 2.8 million in cash, a portion of which includes a potential earn-out.
 

Evotec AG will report its financial results for the first half of 2009 on Friday, August 7, 2009.
 

Evotec AG today announced that a further research milestone, leading to payments to Evotec, has been successfully achieved in its drug discovery collaboration with Boehringer Ingelheim.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced a collaboration with Alios Biopharma, Inc in the area of high throughput screening.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced that it has entered into a research agreement with Cubist Pharmaceuticals, Inc., a leading acute care biopharmaceutical company located in Lexington, Mass., USA.

Evotec-RSIL Ltd. announced today that Ferrer Grupo, the Spanish pharmaceutical and healthcare company has extended their ongoing collaboration.

Evotec AG today announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401.

Evotec AG, a leading provider in the discovery and development of novel small molecule drugs, today announced the expansion of its ion channel capabilities with the addition of unique, ion channel focused libraries and additional electrophysiology screening platforms. 

Evotec AG today reported results and corporate development updates for the first quarter ended March 31, 2009.

Evotec AG today announced that the Company will acquire the zebrafish screening operations of Summit Corporation plc, including operations in Abingdon, UK, and Singapore, for £ 0.5 million in cash.

Evotec AG announced today that in the context of its Evotec 2012 - Action Plan to Focus and Grow, the Company is re-engineering its drug discovery and development operations to improve efficiency and realize further cost saving potential.

Evotec AG announced today that the Supervisory Board proposes at the next Annual General Meeting to be held on June 4, 2009 the election of Dr Walter Wenninger as new member of the Company's Supervisory Board.

Evotec AG today announced the results of a Phase II proof-of-concept study investigating the potential of EVT 302, a reversible and highly selective inhibitor of monoamine oxidase B, as an aid to smoking cessation. 

Evotec AG today announced that it will restructure to focus on core value programs and significantly reduce its operating costs.

Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) today reported financial results for the year ended December 31, 2008.

Evotec AG and Roche announced today that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression.

Evotec AG announced today the appointment of Dr. Werner Lanthaler as Chief Executive Officer of the Company, effective immediately.

Joern Aldag, President and Chief Executive Officer of Evotec OAI, commented: "Following a successful collaboration in the development of our EVOscreen® uHTS system, Novartis has chosen Evotec OAI to support their lead discovery efforts. We are delighted that one of the world's leading R&D organisations has chosen our expertise in drug discovery and our technology platform in this critical area of research."

Evotec SE announced today that the Company has been informed by Bayer about positive Phase IIa results from a study surveying the safety, efficacy and dosage of the compound BAY1817080 in refractory chronic cough. 

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”) based in Seattle, WA, USA for up to US$ 90 m (approx. € 81 m; €/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years. The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash.

Evotec AG today announced that it increases its profitability guidance for the current year after completing its latest financial evaluation. The Company now expects adjusted Group EBITDA to increase by more than 45% (previously: Improve by approx. 30%) in 2018 compared to last year (2017: € 58.4 m). This mainly results from Evotec’s strong business performance leading to increased margin contribution, important scientific milestone achievements in the fourth quarter of 2018 as well as increased other operating income due to e.g. research & development (“R&D”) tax credits in the second half of 2018.

Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.

Evotec AG today decided to begin preparations for legal conversion of the Company into a European Company (Societas Europaea, SE). The proposal, which has already been approved by the Supervisory Board, will be put to a vote at this year’s Annual General Meeting on 20 June 2018.

Evotec AG today announced that it has entered into a definitive agreement with Aptuit Holdings LLC ("Aptuit") under which Evotec will acquire all operational business of Aptuit for $ 300 m (approx. EUR 256 m) to combine the businesses and expand Evotec's role as leading player in integrated outsourced drug discovery and development solutions.

Evotec AG today announced that it resolved on a capital increase from its authorised capital against cash.

Evotec AG announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and development collaboration to identify disease-modifying therapeutics for a broad range of neurodegenerative diseases. Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple other neurodegenerative disorders.

Evotec AG today announced that it has made an offer to acquire Cyprotex PLC (AIM Listing: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK headquartered in UK. The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016.

Evotec AG today announced that, in the context of the half year results published on 10 August 2016, it increases its financial guidance for the current year.

Evotec AG today announced that it increases its financial guidance for the current year.

Evotec AG was informed that US company Hyperion Therapeutics, Inc. is terminating the development of DiaPep277(R) for newly diagnosed Type 1 diabetes.

Evotec AG today announced that it is adjusting its guidance regarding Group revenues.

Evotec AG  today announced that it is adjusting its guidance regarding profitability on operating income for the fiscal year 2012.

Evotec AG that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.

Evotec AG today announced that it has entered into a license and collaboration agreement with Janssen Pharmaceuticals, Inc. with a particular focus on the regeneration of insulin- producing beta cells.

Evotec AG and Roche AG today announced that they have entered into an exclusive world-wide license agreement for the development and commercialisation of Evotec’s MAO-B inhibitor to treat Alzheimer’s disease.